Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Interleukin-1β provided by KIT-competent mast cells is required for KRAS-mutant lung adenocarcinoma.

Lilis I, Ntaliarda G, Papaleonidopoulos V, Giotopoulou GA, Oplopoiou M, Marazioti A, Spella M, Marwitz S, Goldmann T, Bravou V, Giopanou I, Stathopoulos GT.

Oncoimmunology. 2019 Apr 11;8(7):1593802. doi: 10.1080/2162402X.2019.1593802. eCollection 2019.

2.

IκB Kinase α Is Required for Development and Progression of KRAS-Mutant Lung Adenocarcinoma.

Vreka M, Lilis I, Papageorgopoulou M, Giotopoulou GA, Lianou M, Giopanou I, Kanellakis NI, Spella M, Agalioti T, Armenis V, Goldmann T, Marwitz S, Yull FE, Blackwell TS, Pasparakis M, Marazioti A, Stathopoulos GT.

Cancer Res. 2018 Jun 1;78(11):2939-2951. doi: 10.1158/0008-5472.CAN-17-1944. Epub 2018 Mar 27.

3.

Myeloid-derived interleukin-1β drives oncogenic KRAS-NF-κΒ addiction in malignant pleural effusion.

Marazioti A, Lilis I, Vreka M, Apostolopoulou H, Kalogeropoulou A, Giopanou I, Giotopoulou GA, Krontira AC, Iliopoulou M, Kanellakis NI, Agalioti T, Giannou AD, Jones-Paris C, Iwakura Y, Kardamakis D, Blackwell TS, Taraviras S, Spella M, Stathopoulos GT.

Nat Commun. 2018 Feb 14;9(1):672. doi: 10.1038/s41467-018-03051-z.

4.

NRAS destines tumor cells to the lungs.

Giannou AD, Marazioti A, Kanellakis NI, Giopanou I, Lilis I, Zazara DE, Ntaliarda G, Kati D, Armenis V, Giotopoulou GA, Krontira AC, Lianou M, Agalioti T, Vreka M, Papageorgopoulou M, Fouzas S, Kardamakis D, Psallidas I, Spella M, Stathopoulos GT.

EMBO Mol Med. 2017 May;9(5):672-686. doi: 10.15252/emmm.201606978.

Supplemental Content

Loading ...
Support Center